Diuretic peptide conjugates

Details Diuretic peptide conjugates Diuretic peptide conjugates

2005-04-08

2009-06-23

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S326000, C530S327000, C530S328000

Reexamination Certificate

active

07550425

ABSTRACT:
Disclosed are a variety of peptide conjugates represented by the following general formula:in-line-formulae description="In-line Formulae" end="lead"?R1-Z-X-Z′-R2in-line-formulae description="In-line Formulae" end="tail"?including methods of making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides.

REFERENCES:
patent: 5541161 (1996-07-01), Krstenansky et al.
patent: 5688772 (1997-11-01), Estrada et al.
patent: 5763193 (1998-06-01), Houghten et al.
patent: 5837809 (1998-11-01), Grandy et al.
patent: 5840696 (1998-11-01), Lippton
patent: 6025326 (2000-02-01), Steinberg et al.
patent: 6156754 (2000-12-01), Lerchen et al.
patent: 6228840 (2001-05-01), Wei et al.
patent: 6387628 (2002-05-01), Little et al.
patent: WO 98/11125 (1998-03-01), None
patent: WO 99/44627 (1999-09-01), None
patent: WO 99/46283 (1999-09-01), None
patent: WO 01/98324 (2001-12-01), None
patent: WO 02/28412 (2002-04-01), None
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Dayan et al. “Central Injection of RO 64-6198, a Synthetic ORL1 Agonist, Produces Profound Nociceptin-Like Effects of Kidney Function and Feeding, but Not Cardiovascular Function,”FASEB J. 15(5):A1143 (2001).
Dooley et al., “Binding and In Vitro Activities of Peptides with High Affinity for the Nociceptin/Orphanin FQ Receptor, ORL1,”J. Pharmacol. Exp. Ther., 283(2):735-741 (1997).
Kapusta et al. “Diuretic and Antinatriuretic Responses Produced by the Endogenous Opioid-like Peptide, Nociceptin (Orphanin FQ),”Life Sciences, 60(1):PL15-21 (1997).
Kapusta et al. “Central Administration of [Phe1ψ(CH2-NH)Gly2]Nociceptin(1-13)-NH2and Orphanin FQ/Nociceptin (OFQ/N) Produce Similar Cardiovascular and Renal Responses in Conscious Rats,”J. Pharmacol. Exp. Therap. 289(1):173-180 (1999).
Kapusta and Kenigs, “Cardiovascular and Renal Responses Produced by Central Orphanin FQ/Nociceptin Occur Independent of Renal Nerves,”Am. J. Physiol. 277:R987-R995 (1999).
Kapusta, D., “Neurohumoral Effects of Orphanin FQ/Nociceptin: Relevance to Cardiovascular and Renal Funtion,”Peptides21:1081-1099 (2000).
Kapusta et al. “Role of the Renal Nerves in Mediating the Renal Excretory Responses Produced by Central Administration of the Opioid-Like Peptide, Nociceptin, in Conscious Rats,”FASEB. J. 12:A364 (1998).
Kapusta et al. “Central Nociceptin Produces Biphasic Changes in Urine Flow Rate in Conscious Rats via ADH Dependent and Independent Mechanisms,”FASEB J. 13:A457 (1999).
Kapusta et al. “Nociceptin/Orphanin FQ Modulates the Cardiovascular and Renal Responses to Stress Differently in Conscious Spontaneously Hypertensive Rats,”FASEB J. 15(5):A1143 (2001).
Kapusta et al. “Renal Responses to Central Administration of Nociceptin (Orphanin FQ) a Novel Endogenous Opioid-Like Peptide,”J. Am. Soc. Nephrol. 7(9):1536 (1996).
Kapusta et al. “Interaction of Central Mu Opioid and Nociceptin Systems in the Regulation of Renal Excretory Function,”FASEB J. 11:A250 (1997).
Kapusta et al. “Central Administration of a Proposed Nociceptin Receptor Antagonist Produces Nociceptin-Like Cardiovascular and Renal Responses,”J. Am. Soc. Nephrol. 9:308A (1998).
Kenigs et al. “[Nphe1] Nociceptin(1-13)NH2Antagonizes the Cardiovascular Responses to Peripheral, but Not Central Administration of Nociceptin/Orphanin FQ in Conscious Rats,”FASEB J. 15(5):A1142 (2001).
Lapalu et al. “Comparison of the Structure-Activity Relationships of Nociceptin and Dynorphin A Using Chimeric Peptides,”FEBS Letters417(3):333-336 (1997).
Meunier et al. “The Nociceptin (ORL1) Receptor: Molecular Cloning and Functional Architecture,”Peptides21(7):893-900 (2000).
Rizzi et al. “Pharmacological Characterization of the Novel Nociceptin/Orphanin FQ Receptor Ligand, ZP120: In Vitro and In Vivo Studies in Mice,”British J. Pharmacol. 137:369-374 (2002).

Affiliated with

Also associated with

Rating

Diuretic peptide conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diuretic peptide conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diuretic peptide conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4068372